Compare TCMD & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TCMD | STTK |
|---|---|---|
| Founded | 1995 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 300.1M | 275.9M |
| IPO Year | 2016 | 2020 |
| Metric | TCMD | STTK |
|---|---|---|
| Price | $27.88 | $3.77 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 7 |
| Target Price | ★ $27.00 | $6.20 |
| AVG Volume (30 Days) | 265.7K | ★ 810.6K |
| Earning Date | 02-17-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 18.66 | N/A |
| EPS | ★ 0.77 | N/A |
| Revenue | ★ $311,513,000.00 | $1,000,000.00 |
| Revenue This Year | $11.31 | N/A |
| Revenue Next Year | $8.82 | N/A |
| P/E Ratio | $36.41 | ★ N/A |
| Revenue Growth | ★ 9.28 | N/A |
| 52 Week Low | $8.61 | $0.69 |
| 52 Week High | $31.38 | $4.89 |
| Indicator | TCMD | STTK |
|---|---|---|
| Relative Strength Index (RSI) | 37.55 | 39.57 |
| Support Level | $27.00 | $3.52 |
| Resistance Level | $29.16 | $4.10 |
| Average True Range (ATR) | 1.11 | 0.31 |
| MACD | -0.37 | -0.13 |
| Stochastic Oscillator | 8.22 | 1.77 |
Tactile Systems Technology Inc is a medical technology company. The company is engaged in developing and providing medical devices for the treatment of chronic diseases. The firm's proprietary platform flexitouch system provides a home-based solution for lymphedema patients. The entire system is another home solution for patients with chronic swelling and actitouch system for chronic venous insufficiency patients that may be worn throughout the day.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.